調査・レポート
2026年8月30日•1分で読めます
Artificial Sweeteners May Increase HbA1c and Insulin Levels, Study Finds
A large analysis of 21 randomized controlled trials suggests that artificial sweeteners could worsen blood‑sugar control, raising HbA1c and insulin levels.
調査・レポート
2026年8月30日•1分で読めます
Acelra Presents Phase 1 Results of ACL-508 at NLA Conference
Acelra, the new‑drug subsidiary of Jonggeundang, reported Phase 1 data for its CETP inhibitor ACL‑508, aimed at lowering LDL‑C and raising HDL‑C, at the NLA annual meeting in Chicago.
調査・レポート
2026年8月30日•1分で読めます
Nordic Walking Significantly Improves Moderate to Severe Depression Symptoms, Study Finds
A randomized trial of 64 adults shows Nordic walking reduces depressive symptoms within five weeks, especially in severe cases.
調査・レポート
2026年8月30日•1分で読めます
Huons Initiates Phase 2 Trial of Peptide Dry‑Eye Drug HUC1‑394 with First Patient Enrolled
Huons reported first patient enrollment in the Phase 2 study of its peptide‑based dry‑eye candidate HUC1‑394, targeting 150 patients across Korean hospitals.
調査・レポート
2026年8月30日•1分で読めます
Immunomic Therapeutics Completes First Patient Dosing in Phase 1 Trial of ITI-9001 for Japanese Cedar Pollen Allergy
Immunomic Therapeutics reported first patient dosing in a Phase 1 trial of ITI-9001, a Japanese cedar pollen allergy vaccine, with no safety issues observed.